2022 Update from LPBI Group

« From the journal Nature: NFT, Patents, and Intellectual Property: Potential Design

Parasym™ neuromodulation device reveals promising developments in the treatment of heart failure patients with preserved ejection fraction: Clinical Trial Results »

2022 Update from LPBI Group

February 21, 2022 by 2012pharmaceutical

2022 Update from LPBI Group

Author & Curator: Aviva Lev-Ari, PhD, RN

Picture on 2/6/2022

BIO

https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/aviva-lev-ari-phd-rn-founder-lpbi-group-1-0-2-0/

UPDATED on 10/27/2022

On 10/27/2022 LPBI Group’s electronic Scientific Publishing Enterprise consists of the following IP Asset Classes:

IP Asset Class I

Our Journal, PharmaceuticalIntelligence.com has

2,172,224 views
1,367,088 visitors
6,158 scientific articles

The potential revenues from article downloads is explain here

PharmaceuticalIntelligence.com Journal – Projecting the Annual Rate of Article Views

https://pharmaceuticalintelligence.com/vision/pharmaceuticalintelligence-com-journal-projecting-the-annual-rate-of-article-views/

Comparative Websites with that level of Traffic can be found here

Similarweb – Traffic Rank & Website Analysis

Competitive Analysis for our website

Publishers-Media

Please review the following Categories:

Overview
Ranking
Audience
Competitors
Marketing Channels
Outgoing links
Technologies

SOURCE

IP Asset Class II

Our 18 e-Books on Amazon.com – BioMed e-Series

https://lnkd.in/ekWGNqA

These books enjoyed the following remarkable accessibility as PAGE DOWNLOADS



Date		KENP Read
2022		6,041
2021		5,324
2020		12,442
2019		16,415
2018		21,538
2017		20,307
2016		41,736
2015		11,302

Total		135,105

Page downloads launched in July 2015

Combined: all books – Page download by month in a year


Date	KENP Read

Sept 2022	1755
August 2022	645
July 2022	1121
June 2022	296
May 2022	86
April 2022	55
March 2022	278
February 2022	96
January 2022	1709
December 2021	55
November 2021	339
October 2021	142
September 2021	141
August 2021	81
July 2021	114
June 2021	93
May 2021	731
April 2021	114
March 2021	1370
February 2021	95
January 2021	2049
December 2020	184
November 2020	221
October 2020	487
September 2020	1301
August 2020	2258
July 2020	468
June 2020	257
May 2020	4848
April 2020	275
March 2020	554
February 2020	1242
January 2020	347
December 2019	3148
November 2019	495
October 2019	4777
September 2019	883
August 2019	937
July 2019	82
June 2019	1542
May 2019	517
April 2019	818
March 2019	2025
February 2019	148
January 2019	1,043
December 2018	1,792
November 2018	1,361
October 2018	6,733
September 2018	129
August 2018	57
July 2018	206
June 2018	103
May 2018	215
April 2018	681
March 2018	2,961
February 2018	1,616
January 2018	5,684
December 2017	1,016
November 2017	4,742
October 2017	4,447
September 2017	4,911
August 2017	906
July 2017	246
June 2017	510
May 2017	162
April 2017	290
March 2017	557
February 2017	188
January 2017	2,332
December 2016	1,734
November 2016	835
October 2016	3,725
September 2016	40
August 2016	10,613
July 2016	3,849
June 2016	2,968
May 2016	3,091
April 2016	1,436
March 2016	5,728
February 2016	2,677
January 2016	5,040
December 2015	2,216
November 2015	4,129
October 2015	144
September 2015	1,528
August 2015	3,284
July 2015 – PAY PER VIEW STARTS	1

*BOOK Title*	*Date of Publication*	*Number of Pages*	*Page downloads by Aug 2022*
*Perspectives on Nitric Oxide in Disease Mechanisms*	6/21/13	895	11,661
*Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation*	11/30/15	2,760	2,938
*Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics*	11/29/15	3,083	15,486
*Regenerative and Translational Medicine: The Therapeutics Promise for Cardiovascular Diseases*	12/26/15	2,917	3,354
*Genomics Orientations for Personalized Medicine*	11/23/15	2,931	9,680
*Cancer Biology & Genomics for Disease Diagnosis*	8/11/15	3,436	23,603
*Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery*	5/18/17	5,408	7,565
*Metabolic Genomics and Pharmaceutics*	7/21/15	3,482	20,479
*The Immune System, Stress Signaling, Infectious Diseases and Therapeutic Implications*	9/4/17	3,747	15,283
*The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures*	10/16/17	826	4,512
*Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders*	12/9/17	2,862	2,537
*Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics*	12/27/15	2,781	4,665
*Medical 3D BioPrinting – The Revolution in Medicine, Technologies for Patient-centered Medicine: From R&D in Biologics to New Medical Devices*	12/30/17	1,005	6,459
*Pharmacological Agents in Treatment of Cardiovascular Disease*	12/23/18	185	1,032
*Latest in Genomic Methodologies for Therapeutics: Gene Edition, NGS & Bioinformatics, Simulations and the Genome Ontology*	12/1/19		1,968
*Human Reproductive System, Genomic Endocrinology and Cancer Types*	2/1/21		120
*Interventional Cardiology for Disease Diagnosis and Cardiac Surgery for Condition Treatment*	12/24/2018	169	2,008

*Average book length*		2,432

Cumulative Total Page downloads on September 2022

Total

135,105

Page downloads per e-Book and # of Pages in each e-Book

IP Asset Class X

Our Library of 300 Audio Podcasts is found in

Archive for the ‘Interviews with Scientific Leaders’ Category

https://pharmaceuticalintelligence.com/category/interviews-with-scientific-leaders/

IP Asset Class III

Our 100 electronic Proceedings and 40 Tweet Collections of TOP conferences in Biotech and Medicine are here

· Part Two: List of BioTech Conferences 2013 to Present

· Part Three: Conference eProceedings DELIVERABLES & Social Media Analytics

IP Asset Class V

Our Gallery of Biological Images on 10/27/2022 has 6,238 media items

The gallery is accessed from the Dashboard

IP Asset Class XII

Our 18 e-Books Audio Spanish Edition – BioMed e-Series is found here

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/

UPDATED on 10/18/2022

The factors effecting the IP Valuation are described in:

Portfolio of IP Assets

https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/

and

2.0 LPBI is a Very Unique Organization – Section Valuation & Stream of Innovations

https://pharmaceuticalintelligence.com/2021/03/02/2-0-lpbi-is-a-very-unique-organization/

2022 Update from LPBI Group

https://pharmaceuticalintelligence.com/2022/02/21/update-from-lpbi-group/

2.0 LPBI, Strategy #2: Blockchain Transactions Network Ecosystem

https://pharmaceuticalintelligence.com/blockchain-transactions-network/

NFT: Redefined Format of IP Assets

https://pharmaceuticalintelligence.com/nft-redefined-format-of-ip-assets/

Audio English-Spanish: BioMed e-Series

EDICIÓN EN ESPAÑOL

Indice de contenidos electrónico (IDCe)

AUDIO y TEXTO

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/

UPDATED on 10/10/2022

LPBI Group’s elevator Pitch

https://pharmaceuticalintelligence.com/2020/10/20/versions-of-lpbi-groups-elevator-pitch-2-0-lpbi-groups-team-in-our-own-words/

LPBI Group’s ventures need to be positioning us as two ventures:

1.0 LPBI, 2012 – 2020 – a scientific publisher
2.0 LPBI Group, 2021 – 2025 – a software powerhouse with four missions (pipelines)

2022-2023 Elevator Pitch needs to incorporate the following achieved Milestones/accomplishments to date

This Elevator Pitch for 1.0 LPBI, 2012 – 2020 does not include all the PROGRESS accomplished at 2.0 LPBI Group, 2021 – 2025:

https://pharmaceuticalintelligence.com/2020/10/20/versions-of-lpbi-groups-elevator-pitch-2-0-lpbi-groups-team-in-our-own-words/

Status of 2.0 LPBI Group’s four pipelines is as follows:

Mission #1: NLP – completed

NEW GENRE NLP

Genomics Volume Three and
NEW GENRE Cancer Volume One

both include the Text analysis of the respective original volume processed by NLP algorithms: What are the results and the Domain Knowledge Expert interpretation

2.0 LPBI Group’s Mission #1 (Text analysis with AI)

Series B: Genomics

New volume

NEW GENRE Volume Three: Results of Medical Text Analysis with Natural Language Processing (NLP). It is known in 2022, as Genomics Volume Three in NEW GENRE Series B: Frontiers in Genomics Research

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-b-frontiers-in-genomics-research/genomics-volume-2-results-of-medical-text-analysis-with-natural-language-processing-nlp/

Series C: e-Books on Cancer & Oncology NEW GENRE Audio English-Spanish

NEW GENRE Volume One: Cancer Biology and Genomics for Disease Diagnosis

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-c-e-books-on-cancer-oncology/new-genre-volume-one-cancer-biology-and-genomics-for-disease-diagnosis-series-c-volume-1%ef%bf%bc/

PART A:

PART A.1: The eTOCs in Spanish in Audio format AND

PART A.2: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART B:

The graphical results of Medical Text Analysis with Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format

PART C:

The Editorials of the original e-Book in English in Audio format

Mission #2: Blockchain & NFT – work-in-progress

Erich is the Lead
Results of DB Schema Phase 1 will be presented in forthcoming monthly Zoom Board Meetings

Please review

Blockchain Infrastructure we are developing for content monetization [2.0 LPBI Group’s Mission #2]

https://pharmaceuticalintelligence.com/blockchain-transactions-network/

and

NFT minting of our IP [2.0 LPBI Group’s Mission #2]

https://pharmaceuticalintelligence.com/nft-redefined-format-of-ip-assets/

Mission #3: Completion of the Spanish translation of eTOCs for all our 18 BioMed e-Series

For Mission #3 – The 18 books, the Spanish Translation is available
RE-publishing 18 books as NEW GENRE BioMed e-Series before 12/31/2022.
This process involves:

Creation of 18 NEW GENRE Volumes – completed

Audio English-Spanish: BioMed e-Series

EDICIÓN EN ESPAÑOL

Indice de contenidos electrónico (IDCe)

AUDIO y TEXTO

Please review

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/

2. Creation of 18 colored Cover Pages with available Cover Pages Spanish Text – completed

3. Embedding of Audio feature – work-in-progress

4. Upload of all the New Genre Books to Amazon.com – PENDING – to be completed before 12/31/2022

Mission #4: Galectins – Drug discovery with software [2.0 LPBI Group’s Mission #4] – work-in-progress

Dr. Williams is the Lead

Please review

https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/

UPDATED on 4/25/2022

We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022

https://pharmaceuticalintelligence.com/2022/04/25/we-celebrate-ten-years-of-excellence-lpbi-group-4-2012-4-2022/

UPDATED on 3/10/2022

LPBI Group https://pharmaceuticalintelligence.com/

offers the opportunity to play a pivotal role in Founder’s quest for Transfer of Ownership over our Portfolio of 14 IP Asset Classes:

https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/

The vast IP Portfolio of LPBI Group requires an investor as a new owner and a new operating team to celebrate, articulate and position LPBI Group in front of potential 3^rd Party suiters as potential acquirers of the Portfolio of our IP Assets in an advantageous manner to benefit LPBI Group. Since inception, 4/2012, we are self financed and debt free.

The unique strength of LPBI Group is in the following business dimensions:

Market penetration of Existing pharmaceutical and Medical CONTENTS:

+2.1 Million Journal Article Views of +6,100 scientific articles
+147,000 book page downloads, 18 volumes in Medicine

Curation methodology and publishing engine
Composition of Methods unrelated to our Curations as products or our process for creation of curations.
Domain Knowledge Experts.
Transition from e-Scientific Publisher to Software driven business for 2.0 LPBI Group, 2021-2025, a pipeline of four missions: A,B,C,D:

(A) Text Analysis with Artificial Intelligence (NLP, ML, DL) of our own 18 books in Medicine

https://lnkd.in/ekWGNqA

(B) Blockchain IT for content monetization using NFT Auctions

https://pharmaceuticalintelligence.com/nft-redefined-format-of-ip-assets/

B2C (digital content in Life Sciences & Medicine using Ontology searches) and
B2B (auction of drug molecules designed with software by LPBI Group team and by 3^rd parties)

(C) New Genre of Scientific Books: Same 18 Books republish with new content (PART B: NLP) and in new Media (Audio) and in Spanish

https://pharmaceuticalintelligence.com/2021/07/24/proposal-for-new-e-book-architecture-combining-a-bi-lingual-etocs-english-spanish-with-nlps-results-of-medical-text-analysis-series-b-genomics-volume-1-2-and-series-c-cancer-volume-1/

PART A: Spanish Audio, Bi-Lingual Text,
PART B: NLP results and interpretation of the Text Analysis with Machine Learning,
PART C: Editorials Audio

(D) Drug Design with Synthetic Biology Software PRosettaC targeting Galectins. Products will be auctioned on the Blockchain IT Transactions network

https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/

The Methodology of Curation is the tool in use for content creation of the Clinical Interpretations of Scientific Findings reported in experiments and clinical trials in peer reviewed journal articles

Domain knowledge experts:

1.0 LPBI, 2012-2020 – Experts, Authors, Writer (EAW) and Editors

2.0 LPBI, 2021-2025 – EAW engaged in the interpretation of the Text Analysis with NLP visualization results

LPBI Group’s Composition of Methods developed by 1.0 LPBI, 2012-2020 [not related to Curation] includes the following assets:

(a) Platforms of Publishing Scientific Content

(b) Portals,

(d) Multiple Template Systems developed for the production of e-Proceedings and Tweet collections

(e) Schemas and Styles for e-Books eTOCs

(f) Library of 280 Podcasts

(g) Gallery of +6,200 Biological Images

(h) Spanish content

Strategies to be considered:

Keeping LPBI Group’s Portfolio whole, versus
By Asset Class dividing the Portfolio into 14 assets

WebMD established in 1995-97 as 1^st Medical Website. It had 6 businesses going on in parallel. KKR, the acquirer in 7/2017, kept them all together due to synergies derived from cross asset access under one owner https://pharmaceuticalintelligence.com/2017/07/25/ma-of-online-health-publisher-webmd-health-corporation-by-kkr-co-dynamics-in-health-care-media-web-health-and-health-information-markets/

We have done substantial work on documenting what we produced. We are top Thinkers creating Record of Innovations:

See Update on 2/26/2022 https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/aviva-lev-ari-phd-rn-founder-lpbi-group-1-0-2-0/

We seek investor’s view of a New Owner and New management for LPBI Group’s business strategy for prospecting for an acquirer of LPBI Group’s Portfolio of IP Assets.

2022 Update from LPBI Group

This article has five parts:

Part 1: Web Site Statistics

Part 2: 2.0 LPBI Group’s Four Missions: The Pipelines for 2021-2025

Part 3: Portfolio of IP Assets

Part 4: Certificates – One Year Academic Internships in six Disciplines

Part 5: Top 14 Articles by Views, All Time

Part 1: Web Site Statistics

Journal Statistics on April 20, 2022
Total # of Article Views	2,114,157
Total # of Scientific Comments	7,932
Total # of Categories in Journal’s Ontology	743
Total # of Tags	10,653
Total # of Scientific Articles: Curations and Scientific Reports	6,131

2/1/2021 – 2/3/2022 One year Increase in %
Total # of Views	8.59
Total # of Comments	5.41
Total # of Categories	2.06
Total # of Tags	2.03
Total # of Posts	5.41

Top Authors Number of Journal Articles as a Single Author on 3/31/2022	Total Views by Author on 3/31/2022
Aviva Lev-Ari, PhD, RN (N = 3,586)	509,231
Larry H Bernstein, MD, FCAP (N = 1,597)	374,026
Stephen J Williams, PhD (N = 354)	72,783
Tilda Barliya, PhD (N = 52)	70,124
Sudipta Saha, PhD (N = 127)	39,166
Dror Nir, PhD (N = 61)	38,336
Demet Sag, PhD, CRA, GCP (N = 112)	20,074
Ritu Saxena, PhD (N = 39)	17,370
Gail S Thornton, PhD(c) (N = 44)	18,312
Irina Robu, PhD (N = 179)	10,292

Progression of Views by Author By Year – New Graph Updated 2/3/2021

Line Graph Depicting Top Authors Progression by Views Ending 2021-07-01
Date of Production: 2021-07-01

Part 2: Four Missions as 2021 – 2025 Pipelines

2.0 LPBI Missions

Four missions as LPBI’s exposition of the pipelines for

2021 -2025

Mission #1: NLP – Team in USA & India – Medical Text Analysis with NLP – on LPBI 3.3 Giga Bytes of Content. Statistical NLP and Deep Learning by Machine Learning using Wolfram Language for Biological Sciences

Mission #2: Blockchain IT and NLP Processing API generating NLP visualization Products used by Knowledge Graphs stored in Graph Databases – Content monetization infrastructure B2B and B2C.

Scenario from the End User Perspective

Interested parties posing queries to the system (B2C)
System responds by triggering a Recommendation Engine Response (RER) that will fetch: top articles by views
If the article was published in a book THEN the selected Article in the context of all articles in same chapter in the book it was featured will form the article collection for NLP performance.
If article not in a book then in the context of other articles in same categories of research, ones selected by the recommendation engine and ranked by views.
Biological images in these articles will be displayed
NLP results in visual graphics will be displayed
Major Data Science procedures in the back-end are using graph databases for on the Fly generation of NLP results not performed before, thus, not stored in the knowledge graph databases
Domain Knowledge Expert interpretation of the graphics available for selection in several Foreign languages presented in the front-end.
System invokes Blockchain features embedded per LPBI specifications into the API layer(s) of the Blockchain Transactions Network for its cardinal technology features: i.e.,

Permissions
Immutable LEDGER
Smart Contracts
Cyber security of IP assets in blocks

Full feature operations of the Blockchain platform will enable

B2C – Digital Store on a Healthcare Digital Marketplace
B2B – Installation at Big Pharma, Healthcare Insurers and CRO

https://pharmaceuticalintelligence.com/blockchain-transactions-network/

Mission #3: BioMed e-Books – Book Republishing in new GENRE – Bi-Lingual and Multimedia Audio Podcast for Books in the 18-e-Books in five e-Series: A,B,C,D,E

Mission #4: Synthetic Biology Software: Drug discovery Galectins

2.0 LPBI is a Very Unique Organization

Author: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI and 2.0 LPBI, April 2012 to Present

LiSTEN TO THE PODCAST

https://pharmaceuticalintelligence.com/2021/03/02/2-0-lpbi-is-a-very-unique-organization/

Part 3: Portfolio of IP Assets

Data represent the views of LPBI Group’s Founder and by

Dr. Williams

In the Voice of Dr. Williams

https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/

A stream of Ten INNOVATIONS in the Life of LPBI since inception in 2012 to 2021

4/2012 – LPBI was the Launcher of a novel Scientific Curation Methodology for scientific findings in published primary research in the Global e-Scientific Publishing industry https://pharmaceuticalintelligence.com/

As late as 2016, no big publisher, not even one, i.e., Elsevier, John Wiley had curation-based publications: Journals, Books, e-Proceedings or Gallery of thousands of Biological Images as an IP asset class
At LPBI, Curation of scientific findings was performed in +6,000 articles with +2MM e-Views by Global e-Readers

6/2013 – LPBI was the Publisher of the 1^ste-book in Medicine in Kindle Store on the Life Sciences & Medicine Shelf – Upload to this shelf by Amazon.com
2/2021 – Completion of the 18 volumes, BioMed e-Series in five Specialties in Medicine: each article in each volume is a curation-based publication.
On Amazon.com on 7/2021 – LPBI’s e-books in Medicine enjoy +128,100 PAGE DOWNLOADS – the ONE and ONLY publisher in that range of page downloads. The record is the equivalent of 64 books at an average of 2,000 pages a volume !!!! LPBI smallest book is 1,000 pages and its biggest is +3,700 pages
LPBI launched its Natural Language Processing (NLP) Practice in 1/2020 as Mission #1. NLP is one method of Machine Learning (ML). ML is a family of methods in Artificial Intelligence (AI) which is a field in the Computer Science Academic discipline since the early 60s.

In 4/2021 Linguamatics/IQVIA performed NLP on LPBI’s 33 articles and 20 Biological Images. RESULTS: +670 entity relations DISCOVERED by Linguamatics and unknown to Pharma and to Insurers, entity relations between:

Gene-Disease
Gene-Drug
Disease-Drug

These results were jointly presented to a Healthcare Insurer, SLC, UT on 7/13/2021, forthcoming meeting in 9/2021.

LPBI and BurstIQ are architecting NOW the first Natural Language Processing – Blockchain Information Technology infrastructure in existence, This statement is TRUE.

Updated on 7/28/2021: Fluree

Flur.ee, the Web3 Data Platform Open source semantic graph database & LeadSemantics.com presented their solution for NLP and Blockchain on 7/28/2021. Erich G. was lured as Chief architect for LPBI’s Mission #2: NLP & Blockchain

Linguamatics, the leader in NLP did not hear of Blockchain and BurstIQ did not have a request for NLP – LPBI PUT THESE TWO TECHNOLOGIES AND PARTIES TOGETHER

IMAGE SOURCE: BurstIQ image for LPBI

On 7/19/2021 – LPBI had launched LPBI India for Synthetic Biology Software for Drug Discovery targeting Galectins – Collaboration with Dr. Raphael Nir, President and CSO, SBH Sciences, Inc., Natick, MA
On 7/25/2021 – LPBI announced that it will have the NEWLY to be published BioMed e-Books As Mission #3:

A NEW Publishing GENRE of SCIENTIFIC BOOKS

o Bi-Lingual electronic Table Of Contents (eTOCs), English & Spanish with Montero Language Services, Madrid as the Translator of eighteen Books’ Cover Pages and the 18 books electronic Table of Contents.

o The Content promotion in the Spanish speaking Countries with GTO, Madrid as AD Agency.

o NLPs results of Medical Text Analysis with domain knowledge expert Interpretations in Foreign Languages and in Audio: in Spanish and in other languages, forthcoming

o Original English Book – Only Editorials (Preface, Introductions, Summaries and Epilogue) because the Bi-Lingual part has the eTOCs of the e-Book

o This is a new genre and a new architecture of 18 MULTIMEDIA SCIENTIFIC e-Books with (a) NLP results of the Medical Text analysis with machine learning, (b) Expert Interpretation of the Visualization Results. Bi-Lingual Podcasts: (c) eTOCs and (d) Bi-Lingual Expert Interpretation in English and Spanish Text and audio Podcasts, and (e) Books’ Editorials in English Audio Podcast

Content promotion proposal by GTO, Madrid

IMAGE SOURCE: Rendition by GTO, Madrid of BurstIQ Image, above

The Content Monetization effort includes the Price List for LPBI 1.0 digital products and of LPBI 2.0 – NLP Products

Under development

IP Valuation Model per IP asset class is needed to be compared with Master_Financials and to supplement it
Pricing Model and Product Mix Models for the digital products to be generated by the process of Text Analysis with NLP are using a Product Price List already developed.
The scenarios for a Probabilistic Product Mix for the B2B sector are work-in-progress. Scenarios of Product Mix for $500,000 B2B engagements with NLP scaling up with NLP Alliances. The Alliances are the Labor component and LPBI represent Materials (Content) as 25% of the contract price, on top of total, to be paid by the B2B customer as materials in use for the engagement.
B2C Customers on Blockchain will use the Price List for all Digital Products of LPBI 1.0 and LPBI 2.0 – Pay per Use

Part 4: Certificates

One Year Academic Internships in six Disciplines

Certificate One Year

All INTERNSHIPS are TUITION FREE on a VOLUNTEER basis and involve a One Year Academic Training in the following areas.

LPBI Group will run SIX MAJOR INTERNSHIPS: Volunteer base

We Offer esteemed Affiliation, Mentorship by Scientists
NEW skills development in NLP, ML, AI applications to Medical Text and Drug Discovery
References and Resume paragraph on accomplishments and goals during the INTERNSHIP
Opportunity to contribute to Publications
Explorations of opportunities in Life Sciences in the US

Detailed description to be found on each Internship page, below

Part 5: Top 14 Articles by Views, All Time

Updated on 2/22/2022 by Aviva Lev-Ari, PhD, RN

NEW ARTICLE ARE IN THE TOP Fourteen on 3/31/2022

NEW #7: Pyrroloquinoline quinone (PQQ) – an unproven supplement – 7,759 Views, Author: Larry

https://pharmaceuticalintelligence.com/2015/10/15/pyrroloquinoline-quinone-pqq-an-unproved-supplement/

NEW #9: Evolution of Myoglobin and Hemoglobin – 6,417 Views, Author: Larry

https://pharmaceuticalintelligence.com/2015/01/19/life-on-earth-is-traced-to-oxygen-binding/

GRAND TOTAL VIEWS for Top 14 articles on 3/31/2022 is

xx Views

ORIGINAL LIST OF TOP TWELVE ARTICLES on 3/31/2022

Article Name
Live Link

Views
All Time
UPDATED
0n
3/31/2022

Categories of Research

Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?

17,476

Author:

LarryBiological Networks, CANCER BIOLOGY & Innovations in Cancer Therapy, Cell Biology, Disease Biology, Genome Biology, Imaging-based Cancer Patient Management, International Global Work in Pharmaceutical, Liver & Digestive Diseases Research, Metabolomics, Molecular Genetics & Pharmaceutical, Nutrition, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment, Population Health Management, Proteomics, Stem Cells for Regenerative Medicine, Technology Transfer: Biotech and Pharmaceutical | Tagged Adenosine triphosphate, ATP, Glycolysis, Hypoxia-inducible factors, Kreb, Lactate dehydrogenase, Mammalian target of rapamycin, Mitochondrion, Warburg Effect

Recent comprehensive review on the role of ultrasound in breast cancer management

16,788

Author:

Dror NirBiomarkers & Medical Diagnostics, Health Economics and Outcomes Research, Healthcare costs and reimbursement, Imaging-based Cancer Patient Management, Medical Device Therapies for Altzheimer’s Disease, Medical Devices R&D Investment, Medical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound | Tagged breast biopsies, breast cancer, breast cancer management, breast cancer screening, breast cyst, breast lesions, breast ultrasound, mammography, MRI, Personalized medicine, PET, support breast cancer, tomosynthesis, yale university school, yale university school of medicine

Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)

14,562

Author:

AvivaCoagulation Therapy and Internal Bleeding, Electrophysiology, FDA Regulatory Affairs, Origins of Cardiovascular Disease, Pharmacotherapy of Cardiovascular Disease | Tagged Academic Medical Center, Amsterdam, Anticoagulant, Apixaban, Dabigatran, Direct thrombin inhibitor, Direct Xa inhibitor, Food and Drug Administration, New England Journal of Medicine, Non-steroidal anti-inflammatory drug, Northeastern University, PRADAXA, Prothrombin time, Rivaroxaban, VTE, Warfarin

Paclitaxel vs Abraxane (albumin-bound paclitaxel)

16,600

Author:

Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications

10,400

Author:

AvivaCoagulation Therapy and Internal Bleeding, Frontiers in Cardiology and Cardiovascular Disorders, Origins of Cardiovascular Disease, Pharmacotherapy of Cardiovascular Disease, tagged Dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation

Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care

10,064

Author:

AvivaMedical Devices R&D Investment, Nitric Oxide in Health and Disease, Technology Transfer: Biotech and Pharmaceutical | Tagged ARDS, Aviva Lev-Ari, Inhaled Nitric Oxide, nitric oxide, prostacyclin, Pulmonary hypertension, Respiratory failure

Our Team

6,839

Author:

AvivaLPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management
#8
Mesothelin: An early detection biomarker for cancer (By Jack Andraka)6,658

Author:

TildaAdvanced Drug Manufacturing Technology, Bio Instrumentation in Experimental Life Sciences Research, Biological Networks, Gene Regulation and Evolution, Biomarkers & Medical Diagnostics, BioSimilars, CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Prevention: Research & Programs, Cell Biology, Signaling & Cell Circuits, Disease Biology, Small Molecules in Development of Therapeutic Drugs, Health Economics and Outcomes Research, Medical Devices R&D Investment, Nanotechnology for Drug Delivery, Pharmaceutical R&D Investment, Population Health Management, Genetics & Pharmaceutical, Regulated Clinical Trials: Design, Methods, Components and IRB related issues, Technology Transfer: Biotech and Pharmaceutical | Tagged Blood test, carbon nanotubes, early detection, Mesothelin, Pancreatic cancer